Clinicopathological factors for predicting tumor response in hormonal positive/HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

被引：0

作者：

Yincharoen, P. ^{[1
]}

Samarnthai, N. ^{[2
]}

Korphaisarn, K. ^{[3
]}

Imruetaicharoenchoke, W. ^{[1
]}

机构：

[1] Mahidol Univ, Fac Med, Div Head Neck & Breast Surg, Dept Surg,Siriraj Hosp, Bangkok, Thailand

[2] Mahidol Univ, Fac Med, Dept Pathol, Siriraj Hosp, Bangkok, Thailand

[3] Mahidol Univ, Siriraj Hosp, Div Med Oncol, Dept Med,Fac Med, Bangkok, Thailand

来源：

BREAST | 2023年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P112

引用

页码：S57 / S57

页数：1

共 50 条

[41] Abundance of tumor-infiltrating lymphocytes is associated with pathologic complete response to neoadjuvant chemotherapy but not with survival in ER-positive/HER2-negative breast cancer
Wu, Rongrong
Nagahashi, Masayuki
Oshi, Masanori
Miyoshi, Yasuo
Ishikawa, Takashi
Takabe, Kazuaki
CANCER RESEARCH, 2023, 83 (05)
[42] HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?
Landmann, Alessandra
Farrugia, Daniel J.
Diego, Emilia
Bonaventura, Marguerite
Soran, Atilla
Johnson, Ronald
Dabbs, David J.
Clark, Beth
Brufsky, Adam
Davidson, Nancy E.
Lembersky, Barry C.
Jankowitz, Rachel Catherine
Puhalla, Shannon
Ahrendt, Gretchen M.
McAuliffe, Priscilla F.
Bhargava, Rohit
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[43] Axillary Response to Neoadjuvant Therapy in Node-Positive ER-Positive, HER2-Negative Breast Cancer
Friedman-Eldar, Orli
Ozmen, Tolga
Reyes, Fernando Valle
Goel, Neha
Tjendra, Youley
Kesmodel, Susane B.
Moller, Mecker
Franceschi, Dido
Avisar, Eli
ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 2) : S236 - S236
[44] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
Cantini, Luca
Trapani, Dario
Guidi, Lorenzo
Bielo, Luca Boscolo
Scafetta, Roberta
Koziej, Marcin
Vidal, Laura
Saini, Kamal S.
Curigliano, Giuseppe
CANCER TREATMENT REVIEWS, 2024, 123
[45] Real world outcomes of neoadjuvant chemotherapy in ER-positive/PR-positive, HER2-negative breast cancer
Kurian, Matthew
Trybula, Marcus
Patell, Kanchi
Guzik, Gregory
Margevicius, Seunghee
Fu, Pingfu
Montero, Alberto
Martin, James
CANCER RESEARCH, 2024, 84 (09)
[46] Effect of tumor microenvironment on chemotherapy response of patients with triple-negative breast cancer receiving neoadjuvant chemotherapy
Kim, Jae-Joon
Kim, Dongjin
Yu, Yeuni
Jung, Ki Sun
Kim, Yun Hak
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Neoadjuvant Therapy for weak receptor-positive/HER2-negative Breast Cancer
Judith Lorenz, Kuenzell
GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1124 - 1124
[48] Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers
Haeberle, Lothar
Erber, Ramona
Gass, Paul
Hein, Alexander
Niklos, Melitta
Volz, Bernhard
Hack, Carolin C.
Schulz-Wendtland, Ruediger
Huebner, Hanna
Goossens, Chloe
Christgen, Matthias
Doerk, Thilo
Park-Simon, Tjoung-Won
Schneeweiss, Andreas
Untch, Michael
Nekljudova, Valentina
Loibl, Sibylle
Hartmann, Arndt
Beckmann, Matthias W.
Fasching, Peter A.
BREAST CANCER RESEARCH, 2025, 27 (01)
[49] Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients
Arqueros, Cristina
Salazar, Juliana
Gallardo, Alberto
Andres, Marta
Tibau, Ariadna
Bell, Olga Lidia
Artigas, Alicia
Lasa, Adriana
Cajal, Teresa
Lerma, Enrique
Barnadas, Agusti
BIOMEDICINES, 2023, 11 (12)
[50] Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study
Tang, Lingfeng
Shu, Xiujie
Tu, Gang
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)

← 1 2 3 4 5 →